Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples.

Molecular diagnosis & therapy - 1 May 2022

Wang Minghui, Chen Xianshan, Dai Yongmei, Wu Duoguang, Liu Fang, Yang Zheng, Song Baozhi, Xie Li, Yang Liangwei, Zhao Weidi, Zhang Chenxu, Shen Weixi, Fan Chengjuan, Teng Chong, Zhao Xue, Gao Naisheng, Shang Di, Zhao Guofang, Xin Tao

Abstract excerpt

INTRODUCTION: Next-generation sequencing (NGS) enables simultaneous detection of actionable somatic variants and estimation of genomic signatures such as tumor mutational burden (TMB) or microsatellite instability (MSI) status, which empowers therapeutic decisions in clinical oncology. OBJECTIVE: Our retrospective study investigated the clinical performance of somatic variant detection in paired tissue and blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic factors in colorectal cancer

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Microsatellite Instability

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 35305253
DOI: 10.1007/s40291-022-00579-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples.PMID 35305253Read ↗

TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted SequencingSemantic proximity Read ↗

Analytical Validation and Clinical Utilization of the Oncomine Comprehensive Assay Plus Panel for Comprehensive Genomic Profiling in Solid TumorsSemantic proximity Read ↗

Automated next-generation profiling of genomic alterations in human cancers.Semantic proximity Read ↗

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceSemantic proximity Read ↗

Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variantsSemantic proximity Read ↗

Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.Semantic proximity Read ↗

Comparison of Comprehensive Genomic Profiling Testing “Ion Torrent Genexus Sequencer” with FoundationOneSemantic proximity Read ↗

Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapySemantic proximity Read ↗

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read ↗

A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumoursSemantic proximity Read ↗

Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.Semantic proximity Read ↗

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.